<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153160">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068690</url>
  </required_header>
  <id_info>
    <org_study_id>1346.1</org_study_id>
    <secondary_id>2013-004937-34</secondary_id>
    <nct_id>NCT02068690</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Male Subjects (Partially Randomised, Single-blind, Placebo-controlled) and Investigation of Relative Bioavailability and Food Effect of BI 425809 (Open-label, Randomised, Three-way Crossover)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, and pharmacokinetics of BI 425809 following single
      rising doses of BI 425809 in healthy male volunteers; To explore dose proportionality of BI
      425809 as oral drinking solution; To investigate relative bioavailability of BI 425809 oral
      drinking solution fasted compared to BI 425809 tablet fasted and tablet fed
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>frequency [N(%)] of subjects with drug related adverse events (AEs)</measure>
    <time_frame>up to 18 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 192 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 192 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 425809 single rising dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 425809 powder for oral solution (PfOS) in single rising doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 Crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioavailability of BI 425809 PfOS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809 PfOS</intervention_name>
    <description>BI 425809 PfOS</description>
    <arm_group_label>BI 425809 single rising dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>BI 425809 single rising dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>BI 425809 Crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809 tablet</intervention_name>
    <description>BI 425809 tablet</description>
    <arm_group_label>BI 425809 Crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809 PfOS</intervention_name>
    <description>BI 425809 PfOS</description>
    <arm_group_label>BI 425809 Crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male subjects

          -  Age 18 to 45 years (incl.)

          -  Body mass index (BMI) 18.5 to 29.9 kg/m2 (incl.)

          -  Subject must be able to understand and comply with study requirements

        Exclusion criteria:

          -  Any finding in the medical examination (including blood pressure (BP), pulse rate
             (PR) or electrocardiogram (ECG)) deviating from normal and judged clinically relevant
             by the investigator

          -  Repeated measurement of systolic blood pressure &lt;90 or &gt;140 mmHg, or diastolic blood
             pressure &lt;50 or &gt;90 mmHg, or pulse rate &lt;50 or &gt;90

          -  Any laboratory value outside the reference range that the investigator considers to
             be of clinical relevance

          -  Any evidence of a concomitant disease judged clinically relevant by the investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the study
             drug(s)

          -  Diseases of the central nervous system (such as epilepsy), other neurological
             disorders or psychiatric disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1346.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
